Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
1.260
+0.050 (4.13%)
At close: May 15, 2025, 4:00 PM
1.280
+0.020 (1.59%)
After-hours: May 15, 2025, 6:55 PM EDT
Prime Medicine Stock Forecast
PRME's stock price has decreased by -81.08% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Prime Medicine stock ranges from a low of $10 to a high of $18. The average analyst price target of $13.17 forecasts a 945.24% increase in the stock price over the next year.
Price Target: $13.17 (+945.24%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 20, 2025.
Analyst Ratings
The average analyst rating for Prime Medicine stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 → $16 | Strong Buy | Maintains | $15 → $16 | +1,169.84% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +693.65% | Mar 19, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $10 | Buy | Reiterates | $10 | +693.65% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +693.65% | Mar 3, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +1,090.48% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
4.85M
from 2.98M
Increased by 62.62%
Revenue Next Year
17.23M
from 4.85M
Increased by 255.12%
EPS This Year
-1.24
from -1.65
EPS Next Year
-1.20
from -1.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.9M | 84.0M | 141.8M | ||
| Avg | 4.9M | 17.2M | 29.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 533.6% | 1,631.6% | 722.8% | ||
| Avg | 62.6% | 255.1% | 73.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.81 | -0.64 | -0.60 | ||
| Avg | -1.24 | -1.20 | -1.16 | ||
| Low | -1.42 | -1.47 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.